Plasma MicroRNAs Associate Positive, Negative, and Cognitive Symptoms with Inflammation in Schizophrenia

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2025 Jan 8

PMID 39769285

Authors

Takuya Miyano

Masakazu Hirouchi

Naoki Yoshimura

Kotaro Hattori

Tsuyoshi Mikkaichi

Naoki Kiyosawa

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a complex and heterogenous psychiatric disorder characterized by positive, negative, and cognitive symptoms. Our previous study identified three subgroups of schizophrenia patients based on plasma microRNA (miRNA) profiles. The present study aims to (1) verify the reproducibility of the miRNA-based patient stratification and (2) explore the pathophysiological pathways linked to the symptoms using plasma miRNAs. We measured levels of 376 miRNAs in plasma samples of schizophrenia patients and obtained their Positive and Negative Syndrome Scale (PANSS) scores and the Brief Assessment of Cognition in Schizophrenia (BACS) scores. The plasma miRNA profiles identified similar subgroups of patients as in the previous study, suggesting miRNA-based patient stratification is potentially reproducible. Our multivariate analysis identified optimal combinations of miRNAs to estimate the PANSS positive and negative subscales and BACS composite scores. Those miRNAs consistently enriched 'inflammation' and 'NFκB1' according to miRNA set enrichment analysis. Our literature-based text mining and survey confirmed that those miRNAs were associated with IL-1β, IL-6, and TNFα, suggesting that exacerbated positive, negative, and cognitive symptoms are associated with high inflammation. In conclusion, miRNAs are a potential biomarker to identify patient subgroups reflecting pathophysiological conditions and to investigate symptom-related molecular mechanisms in schizophrenia.

References

Nuechterlein K, Nasrallah H, Velligan D . Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities. Schizophr Bull. 2024; 51(2):401-421. DOI: 10.1093/schbul/sbae051. View

Godoy P, Barczak A, DeHoff P, Srinivasan S, Etheridge A, Galas D . Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms. Cell Rep. 2019; 29(12):4212-4222.e5. PMC: 7499898. DOI: 10.1016/j.celrep.2019.11.078. View

Nawwar D, Zaki H, Sayed R . Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. Inflammopharmacology. 2022; 30(5):1891-1907. PMC: 9499910. DOI: 10.1007/s10787-022-01031-w. View

Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T . Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci. 2007; 61(6):602-9. DOI: 10.1111/j.1440-1819.2007.01725.x. View

Rifai N, Gillette M, Carr S . Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24(8):971-83. DOI: 10.1038/nbt1235. View

Martinez B, Peplow P . MicroRNAs as potential biomarkers for diagnosis of schizophrenia and influence of antipsychotic treatment. Neural Regen Res. 2023; 19(7):1523-1531. PMC: 10883514. DOI: 10.4103/1673-5374.387966. View

Sellgren C, Frisell T, Lichtenstein P, Landen M, Askling J . The association between schizophrenia and rheumatoid arthritis: a nationwide population-based Swedish study on intraindividual and familial risks. Schizophr Bull. 2014; 40(6):1552-9. PMC: 4193721. DOI: 10.1093/schbul/sbu054. View

Leirer D, Iyegbe C, Di Forti M, Patel H, Carra E, Fraietta S . Differential gene expression analysis in blood of first episode psychosis patients. Schizophr Res. 2019; 209:88-97. PMC: 6677921. DOI: 10.1016/j.schres.2019.05.011. View

Hertzberg L, Maggio N, Muler I, Yitzhaky A, Majer M, Haroutunian V . Comprehensive Gene Expression Analysis Detects Global Reduction of Proteasome Subunits in Schizophrenia. Schizophr Bull. 2020; 47(3):785-795. PMC: 8084431. DOI: 10.1093/schbul/sbaa160. View

10.

Li J, Han X, Wan Y, Zhang S, Zhao Y, Fan R . TAM 2.0: tool for MicroRNA set analysis. Nucleic Acids Res. 2018; 46(W1):W180-W185. PMC: 6031048. DOI: 10.1093/nar/gky509. View

11.

Dainese P, Wyngaert K, De Mits S, Wittoek R, Van Ginckel A, Calders P . Association between knee inflammation and knee pain in patients with knee osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2021; 30(4):516-534. DOI: 10.1016/j.joca.2021.12.003. View

12.

Goldsmith D, Haroon E, Miller A, Strauss G, Buckley P, Miller B . TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res. 2018; 199:281-284. PMC: 6111000. DOI: 10.1016/j.schres.2018.02.048. View

13.

Correll C, Schooler N . Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020; 16:519-534. PMC: 7041437. DOI: 10.2147/NDT.S225643. View

14.

Lai C, Yu S, Hsieh M, Chen C, Chen H, Wen C . MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One. 2011; 6(6):e21635. PMC: 3126851. DOI: 10.1371/journal.pone.0021635. View

15.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

16.

Schwarz E, Guest P, Steiner J, Bogerts B, Bahn S . Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry. 2012; 2:e82. PMC: 3309553. DOI: 10.1038/tp.2012.3. View

17.

Kumari S, Malik M, Florival C, Manalai P, Sonje S . An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS). J Addict Res Ther. 2018; 8(3). PMC: 5805140. DOI: 10.4172/2155-6105.1000324. View

18.

Grosu S, Dobre M, Milanesi E, Hinescu M . Blood-Based MicroRNAs in Psychotic Disorders-A Systematic Review. Biomedicines. 2023; 11(9). PMC: 10525934. DOI: 10.3390/biomedicines11092536. View

19.

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F . A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6):R64. PMC: 2718498. DOI: 10.1186/gb-2009-10-6-r64. View

20.

Duan S, Gao R, Xing Q, Du J, Liu Z, Chen Q . A family-based association study of schizophrenia with polymorphisms at three candidate genes. Neurosci Lett. 2005; 379(1):32-6. DOI: 10.1016/j.neulet.2004.12.040. View